Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

NCT03458325 is registered in ClinicalTrials.gov with scPharmaceuticals, Inc. as lead sponsor.

NCT NCT03458325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03458325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor
Lead sponsor
scPharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2020
Completion date
June 24, 2021
Enrollment
27 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure